Biomarkers: A Market Briefing

Table of Contents

Chapter One: Executive Summary

• The Importance of Biomarkers
  • Speed Drug Development
  • Predictive Diagnostics
• Key Applications
  • Selected Clinical Trial Applications
  • Key Diagnostics
• World Market Summary
  • Clinical Diagnostics
  • Clinical Trials
• Methodology

Chapter Two: Introduction

• In Perspective
  • What Are Biomarkers?
  • Surrogate Endpoints
• Types of Biomarkers
  • Applications
    • Diagnostics
    • Drug Development
    • Imaging Biomarkers
  • Issues and Concerns

Chapter Three: Markets

• Overview
• Key Diagnostics Segments
  • Cancer
  • EGFR Testing
  • Stroke
  • Drug Development
  • Clinical Trials

Chapter Four: COMPANY Profiles

• 4.1 Biophysical Corp.
• 4.2 Charles River Laboratories Inc.
• 4.3 Cyclacel Pharmaceuticals Inc.
• 4.4 deCODE Genetics
• 4.5 Enodar Biologic Corp.
• 4.6 Health Discovery Corp.
• 4.7 Illumina Inc.
• 4.8 Imgenex Corp.
• 4.9 Insilicos LLC
• 4.10 Metabolon Inc.
• 4.11 Millennium Pharmaceuticals Inc.
• 4.12 Peakadilly
• 4.13 PPD Inc.
• 4.14 Proteome Sciences plc
• 4.15 Rules-Based Medicine Inc.
• 4.16 Targeted Molecular Diagnostics LLC

List of Exhibits

• Exhibit 1-1: World Market for Biomarkers in HER2 Breast Cancer Diagnostics 2006-2010
• Exhibit 1-2: World Market for Biomarkers in Ovarian Cancer Diagnostics 2006-2010
• Exhibit 1-3: World Market for Biomarkers in Cervical Cancer Diagnostics 2006-2010 Revenues (in millions)
• Exhibit 1-4: Summary: World Market for Biomarkers in Clinical Trials 2006-2010
• Exhibit 3-1: U.S. Market for HER2-Based Biomarkers for Breast Cancer 2006-2010
• Exhibit 3-2: World Market for HER2-Based Biomarkers for Breast Cancer 2006-2010 Revenues (in millions)
• Exhibit 3-3: US Market for Biomarkers for Ovarian Cancer 2006-2010
• Exhibit 3-4: Market for Biomarkers for Ovarian Cancer 2006-2010
• Exhibit 3-5: Market for Biomarkers for Cervical Cancer 2006-2010
• Exhibit 3-6: World Market for Biomarkers for Cervical Cancer 2006-2010
• Exhibit 3-7: US Market for Biomarkers for Prostate Cancer 2006-2010
• Exhibit 3-8: World Market for Biomarkers for Prostate Cancer 2006-2010
• Exhibit 3-9: US Market for Biomarkers for Bladder Cancer 2006-2010
• Exhibit 3-10: World Market for Biomarkers for Bladder Cancer 2006-2010
• Exhibit 3-11: US Market for Biomarkers for EGFR Testing 2006-2010
• Exhibit 3-12: World Market for Biomarkers for EGFR Testing 2006-2010
• Exhibit 3-13: US Market for Biomarkers for Stroke Diagnosis 2006-2010
• Exhibit 3-14: World Market for Biomarkers for Stroke Diagnosis 2006-2010
• Exhibit 3-15: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2006
• Exhibit 3-16 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2006
• Exhibit 3-17: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2007
• Exhibit 3-18 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2007
• Exhibit 3-19: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2008
• Exhibit 3-20 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2008
• Exhibit 3-21: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2009
• Exhibit 3-22 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2009
• Exhibit 3-23: U.S. Clinical Trial Market for Biomarkers by Phase (Number of Trials, Patients, Biomarker Patients, Cost per Test, Market Size) 2010
• Exhibit 3-24 : World Clinical Trial Market for Biomarkers by Geographical Region (U.S., European Union, Asia) 2010